US9186401033 - Common Stock
VACCINEX INC
NASDAQ:VCNX (9/27/2023, 11:41:10 AM)
1.18
-0.08 (-6.35%)
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 38 full-time employees. The company went IPO on 2018-08-09. The company discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab’s mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
VACCINEX INC
1895 Mount Hope Ave
Rochester NEW YORK 14620
P: 15852712700.0
CEO: Maurice Zauderer
Employees: 38
Website: https://www.vaccinex.com/
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Tuesday?
Tuesday's session: gap up and gap down stocks
Pre-market stock analysis on 2023-09-26: top gainers and losers in today's session.
Here you can normally see the latest stock twits on VCNX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: